

Special Issue

Poxviruses: From Pathophysiology to Novel Therapeutic Approaches

Message from the Guest Editor

We recently celebrated the 40th anniversary of smallpox eradication, but the interest in poxviruses is still high for several reasons. Namely, their double-stranded DNA genome can easily be manipulated, and introductions of heterologous genes are kept stable over multiple viral passages. These features have been exploited to generate recombinant poxviruses for application in biomedical research.

In particular, attenuated vaccinia virus strains have been becoming increasingly popular as vectors in various vaccination programs, and the feasibility of using poxviruses to specifically destroy tumor cells is being tested. However, there is still much to learn about poxviruses in order to improve their safety and efficacy in translational applications. Each of the more than 200 viral-encoded proteins gives us the opportunity to extend our knowledge about fundamental cell biology mechanisms and the function of the immune system in different species. Thus, this Special Issue invites authors from any research field to contribute to this area of biomedicine, either with original data or with literature reviews.

Guest Editor

Dr. Michael H. Lehmann

Institute for Infectious Diseases and Zoonoses, Ludwig-Maximilians-Universität München, 85764 Oberschleißheim, Germany

Deadline for manuscript submissions

closed (30 June 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/39933

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).